Akero Therapeutics Advances in MASH Treatment Research

Akero Therapeutics ( (AKRO) ) has released its Q1 earnings. Here is a breakdown of the information Akero Therapeutics presented to its investors.

Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH), with its lead product candidate, efruxifermin (EFX), currently in Phase 3 clinical trials.

In its first quarter of 2025, Akero Therapeutics reported significant progress in its clinical trials, particularly with the Phase 2b SYMMETRY study, which showed a statistically significant reversal of compensated cirrhosis due to MASH after 96 weeks of treatment with EFX. The company also raised $402.5 million through a public offering, bolstering its financial position.

The SYMMETRY study results, published in the New England Journal of Medicine, highlighted EFX’s potential as a first-in-class therapy for MASH-related cirrhosis. Key findings included a notable improvement in fibrosis among patients treated with EFX compared to placebo, as well as significant reductions in liver stiffness and ELF scores. Additionally, Akero presented promising data from its HARMONY study at the EASL Congress 2025, showcasing EFX’s efficacy in reversing fibrosis in pre-cirrhotic MASH patients.

Financially, Akero ended the quarter with $1,128 million in cash and marketable securities, positioning the company to fund its operations into 2028. The company’s total operating expenses increased to $80.9 million, driven by ongoing Phase 3 studies and increased personnel costs.

Looking ahead, Akero’s management remains optimistic about the potential of EFX to transform MASH treatment, with ongoing Phase 3 SYNCHRONY trials expected to provide further insights into the drug’s efficacy and safety. The company is well-positioned financially to continue its research and development efforts, aiming to address the high unmet medical need in MASH treatment.